Biogen Idec agrees to pay $32.5 million upfront for preclinical CNS antibody portfolio

Biogen Idec has agreed to pay $32.5 million up front and up to $395 million in milestone payments for three preclinical immunotherapy programmes from its partner Neurimmune.